Literature DB >> 2427837

Effects of high doses of celiprolol in asthmatic patients.

H D Doshan, R Brown, W J Applin, M Kapoor, F S Caruso.   

Abstract

Sixteen normotensive asthmatic patients received single doses of 400 and 600 mg of celiprolol and 100 mg of atenolol in this placebo-controlled, double-blind crossover study. Pulmonary function was assessed by spirometry. Changes in forced one-second expiratory volume (FEV1) and mid-maximal expiratory flow (MMEF) following both doses of celiprolol were indistinguishable from the effects of placebo, whereas atenolol caused a significant reduction in both measurements of pulmonary function. Graded doses of albuterol, a beta 2-selective sympathomimetic administered at 15-min intervals starting 3 h after each treatment, as expected, caused bronchodilation. The overall bronchodilatory effects of this combined, beta-blocker plus albuterol treatment on pulmonary function were greatest after celiprolol 600 mg, followed in order by celiprolol 400 mg, placebo, and atenolol. Celiprolol 400 mg and 600 mg neither caused bronchoconstriction nor antagonized albuterol in this acute study. Because of its bronchosparing properties, even at high doses, celiprolol may offer an advantage over other, similar agents in the treatment of hypertension and angina in asthmatics.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2427837     DOI: 10.1097/00005344-198608004-00024

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  7 in total

1.  Selectivity of antagonist and partial agonist activity of celiprolol in normal subjects.

Authors:  N M Wheeldon; D G McDevitt; B J Lipworth
Journal:  Br J Clin Pharmacol       Date:  1992-10       Impact factor: 4.335

Review 2.  Evaluation of celiprolol, a new cardioselective beta 1-adrenergic blocker with vasodilating properties, in the treatment of mild to moderate hypertension in the elderly.

Authors:  K D Lamon
Journal:  Cardiovasc Drugs Ther       Date:  1991-01       Impact factor: 3.727

Review 3.  Drug-induced respiratory disorders: incidence, prevention and management.

Authors:  L Ben-Noun
Journal:  Drug Saf       Date:  2000-08       Impact factor: 5.606

Review 4.  Celiprolol. An evaluation of its pharmacological properties and clinical efficacy in the management of hypertension and angina pectoris.

Authors:  C J Dunn; C M Spencer
Journal:  Drugs Aging       Date:  1995-11       Impact factor: 3.923

5.  Comparative effects of celiprolol, propranolol, oxprenolol, and atenolol on respiratory function in hypertensive patients with chronic obstructive lung disease.

Authors:  R Fogari; A Zoppi; F Tettamanti; L Poletti; G Rizzardi; G Fiocchi
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

Review 6.  Celiprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties and its therapeutic use in hypertension and angina pectoris.

Authors:  J G Riddell; R G Shanks; R N Brogden
Journal:  Drugs       Date:  1987-10       Impact factor: 9.546

7.  A dose-ranging study to evaluate the beta-adrenoceptor selectivity of single doses of betaxolol.

Authors:  N A Irvine; B J Lipworth; D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1990-07       Impact factor: 4.335

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.